KalVista Pharmaceuticals, Inc. (KALV)
| Market Cap | 985.01M |
| Revenue (ttm) | 73.62M |
| Net Income (ttm) | -164.29M |
| Shares Out | 51.22M |
| EPS (ttm) | -3.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 712,434 |
| Open | 19.56 |
| Previous Close | 19.16 |
| Day's Range | 18.99 - 20.12 |
| 52-Week Range | 9.83 - 21.31 |
| Beta | -0.40 |
| Analysts | Strong Buy |
| Price Target | 32.60 (+69.44%) |
| Earnings Date | Jul 9, 2026 |
About KALV
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmace... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price target is $32.6, which is an increase of 69.44% from the latest price.
News
KalVista Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
EKTERLY's launch has seen rapid uptake in the US, Germany, and Japan, with strong physician and patient satisfaction and over 20% market penetration. Formulary access is expanding, pediatric and short-term prophylaxis opportunities are advancing, and the company is well-funded to reach profitability.
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham ...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five ne...
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (se...
KalVista Pharmaceuticals Transcript: Transition period
EKTERLY's U.S. launch drove $49.1M in eight-month revenue, with rapid adoption and strong patient and physician satisfaction. Global expansion is underway, and EKTERLY is now a first-line therapy for adolescents, supporting long-term growth.
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a co...
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted f...
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review t...
KalVista Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
The conference highlighted the rapid adoption of a new oral on-demand HAE therapy, which is driving earlier and more frequent treatment of attacks, expanding market potential, and shifting patient and prescriber behavior. Growth is strong, with refill rates and sales exceeding expectations.
KalVista Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Ekterly's launch has exceeded expectations, driven by robust clinical data, strong physician and patient satisfaction, and effective support services. Revenue is increasingly driven by refills, with high-burden patients adopting at above-average rates. The company is focused on expanding indications and maintaining its first-mover advantage.
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 Ameri...
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following up...
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management ...
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy o...
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug
KalVista Pharmaceuticals Inc. (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescripti...
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited gl...
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted market...
KalVista Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
EKTERLY's rapid adoption as the first oral HAE therapy has driven strong market penetration and high patient satisfaction, with severe disease patients leading early uptake. Commercial processes are streamlining, international launches are underway, and the product's safety and convenience are reinforcing its market position.
KalVista Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
EKTERLY’s launch has seen rapid adoption, especially among high-attack-rate HAE patients, with strong revenue and positive feedback. Payer coverage is progressing, and international expansion is underway, focusing on Europe and Japan with a lean commercial model.
KalVista Pharmaceuticals Earnings Call Transcript: Q3 2026
EKTERLY's launch drove $13.7M in sales with rapid adoption among high-burden HAE patients and strong refill rates. International expansion is progressing, and payer access is expected to broaden in 2026. The company is fully funded through profitability.
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended ...
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY...
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review ...
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for ...
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), t...